Autolus Therapeutics: Navigating A Bumpy 2026

Galzus Research Investing Group Follow 5 Share Save Play ( 9min ) Comments Summary Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel’s expansion into lupus nephritis and multiple sclerosis represents significant long-term upside, with pivotal data expected in 2027–2028 and a potentially underserved market niche. Despite modest revenue growth and a positive gross margin, AUTL faces a short cash runway, relying on restructuring and sales growth to extend liquidity into Q4 2027. Near-term catalysts are limited, and the investment thesis is long-term positive but remains high risk due to delayed clinical milestones and ongoing operational pressures. Looking for a portfolio of ideas like this one? Members of The Total Pharma Tracker get exclusive access to our subscriber-only portfolios. Learn More » Richard Drury/DigitalVision via Getty Images Topline Summary And Update Since I started covering Autolus Therapeutics plc ( AUTL ) over a year ago , I've remained optimistic about the potential for their CAR T-cell therapy pipeline, particularly as they've continued to This article was written by Galzus Research 4.03K Followers Follow I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.